Clinical Laserthermia Systems AB represents a strong commitment to advancing the field of cancer treatment through innovative and cutting-edge technologies. The company's corporate philosophy is centered around delivering highly effective and personalized treatment solutions to improve patients' quality of life. Clinical Laserthermia Systems AB focuses on providing safe and efficacious treatments that involve minimally invasive laser ablation therapies. With a dedication to research and development, the company aims to revolutionize cancer treatment by continually improving their offerings and embracing the latest medical advancements. Clinical Laserthermia Systems AB is known for its patient-centric approach, striving to address the unique needs and challenges of individuals battling cancer.

Clinical Laserthermia Systems AB is primarily present in Sweden, as it is a Swedish-based company.

Clinical Laserthermia Systems AB has achieved several significant milestones in its operations. These include securing regulatory approvals for its advanced medical devices and treatment techniques, which have revolutionized the field of oncology. The company has successfully conducted clinical trials and achieved positive patient outcomes, cementing its position as a leader in the development of minimally invasive cancer treatments. Additionally, Clinical Laserthermia Systems AB has expanded its global presence by establishing strategic partnerships with key healthcare providers and distributors worldwide. These achievements reflect the company's dedication to advancing the treatment of cancer and improving patient outcomes.

Clinical Laserthermia Systems AB is a renowned medical technology company that specializes in developing and commercializing advanced minimally invasive cancer treatment solutions. Established in [year of establishment], Clinical Laserthermia Systems AB has a strong background in utilizing laser technology for improving cancer treatment outcomes. The company has achieved significant milestones over the years and is recognized for its innovative methods in precision thermal therapy. Clinical Laserthermia Systems AB has a dedicated team of experts who continue to push the boundaries of cancer treatment, offering hope and enhanced quality of life for patients worldwide.

The main competitors of Clinical Laserthermia Systems AB in the market include other companies specializing in medical laser systems and therapies. These may include established players in the medical device industry, such as Medtronic, Johnson & Johnson, and Boston Scientific, as well as emerging companies focusing on innovative laser technologies for medical applications. These competitors provide similar or alternative solutions for minimally invasive treatments and medical procedures.

Clinical Laserthermia Systems AB is primarily active in the healthcare and medical industry.

The business model of Clinical Laserthermia Systems AB revolves around providing innovative and advanced laser technology solutions for minimally invasive cancer treatments. The company specializes in the development, manufacturing, and marketing of the TRANBERG®|Thermal Therapy System, which enables precision and controlled tumor ablation. Clinical Laserthermia Systems AB aims to improve the standard of care for cancer patients by offering safe and effective treatment options that minimize risks and side effects. This Swedish-based company focuses on research, collaboration, and adopting cutting-edge technologies to deliver breakthrough solutions in the field of oncology.

De Clinical Laserthermia Systems K/W is -3,65.

De Clinical Laserthermia Systems KUV is 0,35.

De AlleAktien Kwaliteitsscore voor Clinical Laserthermia Systems is 4/10.

De verwachte Clinical Laserthermia Systems omzet is 45,32 mln. SEK.

De verwachte Clinical Laserthermia Systems winst is -4,30 mln. SEK.

The company Clinical Laserthermia Systems AB (CLS) is a leading provider of medical technology in the field of minimally invasive cancer therapy. CLS's business model is focused on offering its customers innovative technologies and services for effective cancer treatment. The company has several divisions that focus on different areas of cancer treatment. One of the main divisions is the development and manufacturing of devices for laser therapy. CLS's flagship product, the TRANBERG®|Thermal Therapy System, is an innovative technology for the minimally invasive treatment of gliomas and other brain tumors. This method allows for precise localization of tumors and targeted treatment with focused radiation doses. Another division of CLS is the development and marketing of services related to laser therapy. Here, the company focuses on acquiring customers such as hospitals, clinics, and other medical facilities interested in adopting this new technology. CLS has built a network of experts to provide training, certifications, and technical support to optimize clinical outcomes. CLS's business model is also designed to generate sustainable revenue through the sale of consumables and accessories. This includes sterile disposable probes and catheters necessary for the application of laser therapy. The company has established a strong distribution network to distribute its products worldwide. Another important element of CLS's business model is close collaboration with research institutions and clinics. The company continuously works on developing new treatment options and technologies that can improve clinical practice. By collaborating with scientists and physicians, CLS can ensure that its products and services are based on the latest research findings. Overall, CLS's business model aims to provide a complete range of products, services, and support to medical facilities interested in cancer treatment. The company is committed to constantly improving clinical practice and enhancing the quality of life for people affected by cancer. With its innovative technologies and comprehensive services, CLS has established itself as a leading provider of medical technology for cancer treatment.

Clinical Laserthermia Systems keert een dividend van 0 SEK uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Clinical Laserthermia Systems of het bedrijf keert geen dividend uit.

De ISIN van Clinical Laserthermia Systems is SE0002756130.

Het WKN van Clinical Laserthermia Systems is A12CNJ.

De ticker van Clinical Laserthermia Systems is CLS B.ST.

Binnen de laatste 12 maanden betaalde Clinical Laserthermia Systems een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Clinical Laserthermia Systems naar verwachting een dividend van 0 SEK betalen.

De dividendrendement van Clinical Laserthermia Systems is momenteel .

Clinical Laserthermia Systems betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Clinical Laserthermia Systems betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 SEK verwacht. Dit komt overeen met een dividendrendement van 0 %.

Clinical Laserthermia Systems wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Clinical Laserthermia Systems van 25-11-2024 ter hoogte van 0 SEK te ontvangen, moest je het aandeel voor de ex-datum op 25-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 25-11-2024.

In het jaar 2023 heeft Clinical Laserthermia Systems 0 SEK aan dividenden uitgekeerd.

De dividenden van Clinical Laserthermia Systems worden in SEK uitgekeerd.